MAX Chat
Company Analysis China Regenerative Medicine International Limited
1. Summary
Advantages
- The stock's return over the last year (375%) is higher than the sector average (16.48%).
- Current debt level 36.18% is below 100% and has decreased over 5 years from 91.49%.
- The company's current efficiency (ROE=95.98%) is higher than the sector average (ROE=3.98%)
Disadvantages
- Price (0.475 HK$) is higher than fair price (0.3369 HK$)
- Dividends (0%) are below the sector average (4.32%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| China Regenerative Medicine International Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | 2.2% | 3.9% | 3.3% |
| 90 days | 37.7% | 0.7% | 16% |
| 1 year | 375% | 16.5% | 42.5% |
8158 vs Sector: China Regenerative Medicine International Limited has outperformed the "Healthcare" sector by 358.52% over the past year.
8158 vs Market: China Regenerative Medicine International Limited has outperformed the market by 332.47% over the past year.
Stable price: 8158 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 8158 with weekly volatility of 7.21% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (0.475 HK$) is higher than the fair price (0.3369 HK$).
Price is higher than fair: The current price (0.475 HK$) is 29.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (4.54) is lower than that of the sector as a whole (37.2).
P/E vs Market: The company's P/E (4.54) is lower than that of the market as a whole (43.79).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.2) is higher than that of the sector as a whole (1.93).
P/BV vs Market: The company's P/BV (3.2) is higher than that of the market as a whole (1.59).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.8898) is lower than that of the sector as a whole (4.03).
P/S vs Market: The company's P/S indicator (0.8898) is lower than that of the market as a whole (2.5).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (41.58) is higher than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (41.58) is higher than that of the market as a whole (9.93).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -20.88% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-20.88%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (95.98%) is higher than that of the sector as a whole (3.98%).
ROE vs Market: The company's ROE (95.98%) is higher than that of the market as a whole (2.89%).
5.5. ROA
ROA vs Sector: The company's ROA (11.04%) is higher than that of the sector as a whole (2.89%).
ROA vs Market: The company's ROA (11.04%) is higher than that of the market as a whole (3.12%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (20.88%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '4.32%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.67.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 2 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
